CBG/CBD oil for nerve pain from chemotherapy
Part of Brain & nervous system, Cancer, Pain clinical trials.
This trial tests whether a blend of CBG and CBD oils can help relieve nerve pain, tingling, or weakness caused by platinum-based chemotherapy in people with certain gastrointestinal cancers. If you have had colorectal, biliary, pancreatic, esophageal, gastric, or small intestinal cancer and completed chemo in the last 2 years, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 years old or older.
- You have nerve pain, tingling, or muscle weakness from chemotherapy that has lasted more than 2 weeks.
- You had platinum-based chemotherapy for colorectal, biliary, pancreatic, esophageal, gastric, or small intestinal cancer within the past 2 years.
- You are not currently taking other treatments for nerve pain, or you can stop them at least 2 weeks before starting the study.
- You do not have a history of nerve damage before chemotherapy.
- You are a patient at Penn State Health.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a gentle, non-invasive brain stimulation (over the motor cortex) can help relieve pain caused by nerve damage from chemotherapy. It is for people who have completed cancer treatment at least 3 months ago and have ongoing painful neuropathy.
This trial tests whether a cannabis-based product can reduce nerve damage (neuropathy) caused by chemotherapy in people who have finished treatment for breast or colon cancer. It focuses on survivors who still have pain, numbness, or tingling in their hands or feet.
This study tests a diet program delivered online to help reduce nerve damage symptoms like numbness and tingling caused by chemotherapy. It is for cancer survivors who completed treatment and still have these symptoms.
This study tests a new gel (VMD-3866) applied to the skin to treat moderate nerve pain, numbness, or tingling caused by previous chemotherapy. It aims to see if the gel can safely reduce pain for people whose symptoms have been stable for at least 8 weeks.
This Phase 2 trial tests duloxetine to see if it safely reduces painful nerve damage caused by chemotherapy (especially taxanes) in people with solid tumors. If you have moderate-to-severe nerve pain and meet lab and heart-safety checks, this study may be an option.
This study looks at “TRP channels,” which are part of how nerves sense pain and temperature, to understand nerve pain (neuropathy) after chemotherapy. It may help improve how future treatments prevent or reduce nerve pain in people who have had certain chemotherapy drugs.
Hear when a new Chemotherapy-induced Peripheral Neuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.